{'fraction_non_alphanumeric': 0.02247191011235955, 'fraction_numerical': 0.0, 'mean_word_length': 5.31496062992126, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
All Patients With Advanced Fibrosis Should Continue to Be Screened for Hepatocellular Carcinoma After Sustained Virological Response of Hepatitis C Virus

• It is not clear how much fibrosis regression occurs in those patients with hepatitis C virus (HCV) who achieve sustained virological response (SVR), especially because the available diagnostic tools such as transient elastography (TE) and laboratory markers have not been validated for documenting fibrosis regression. • There is not yet enough information to evaluate the decrease in fibrosis and hepatocellular carcinoma (HCC) risk after SVR with the new direct-acting antivirals (DAAs). • A decrease in fibrosis after SVR with DAAs may not translate to a significant enough decrease in HCC risk to the point we should stop screening for HCC.